Breakthrough Vaccine for RSV Prevention in Older Adults
Pfizer has revealed that its vaccine candidate for respiratory syncytial virus (RSV), PF-06928316 or RSVpreF, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the prevention of lower respiratory tract disease associated with RSV in individuals aged 60 years and above.
The FDA's decision was primarily influenced by the promising outcomes from a proof-of-concept, Phase 2a study.
This study assessed the safety, immunogenicity, and efficacy of a single 120µg dose of RSVpreF in a human viral challenge model involving healthy adults aged 18 to 50 years.
RSV is a highly transmissible virus that commonly leads to respiratory illnesses, presenting a major health risk. Infants, children with chronic medical conditions, and older adults are especially susceptible to its severe impacts.
This viral infection can have significant consequences, necessitating heightened attention and care for these vulnerable populations.
RSV infections impose a significant public health burden in the United States. Annually, RSV leads to a substantial number of hospitalizations (approximately 177,000) and fatalities (14,000) among older adults.
Likewise, children under the age of five experience a considerable number of outpatient visits (approximately 2.1 million) and hospitalizations (58,000) due to RSV-related illnesses. These statistics underscore the noteworthy impact of RSV on both older adults and young children in the United States.
Currently, there are no preventive, curative, or vaccine interventions available for RSV in older adults, leaving the medical community with limited options. Supportive care remains the primary approach for managing the illness in adults affected by RSV.
